title: Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007.
abstract: Liver disease due to hepatitis C virus (HCV) infection is a leading cause of non-AIDS-related morbidity and mortality in patients infected with HIV. We assessed the frequency of and predictors for initiation of treatment for HCV infection among patients coinfected with HCV/HIV enrolled in the HIV Outpatient Study (HOPS) during 1999-2007. We included patients with confirmed HCV infection, at least 1 year of subsequent follow-up, and no evidence of prior HCV treatment. We assessed predictors of HCV treatment initiation using Cox proportional hazards analyses. During 1999-2007, 103 (20%) HOPS patients coinfected with HCV/HIV initiated HCV treatment during a median of 4.3 years of follow-up (interquartile range: 2.7, 6.7). In multivariable analysis, non-Hispanic black race/ethnicity (hazard ratio HR] 0.3; 95% confidence interval [CI] = 0.2, 0.6) was independently associated with a lower likelihood of HCV treatment. Elevated alanine aminotransferase (ALT; HR 3.5; 95% CI = 2.2, 5.6) and CD4+ cell count ≥500 cells/mm(3) (HR 1.8; 95% CI = 1.2, 2.8) at the start of observation were independently associated with higher likelihood of HCV treatment. For patients starting observation in 1999-2001, 2002-2004 and 2005-2007, 5%, 11% and 21% of patients initiated treatment during the first year of follow-up, respectively. Between 1999 and 2007, despite a stable low fraction of patients coinfected with HCV/HIV initiating treatment for HCV infection, an increasing proportion initiated treatment within the first year after the infection was confirmed. Treatment of HCV infection in patients coinfected with HCV/HIV should be considered a priority, given the increased risk of accelerated end-stage liver disease.
authors.affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. cvellozzi@cdc.gov
authors.forename: C
authors.initials: C
authors.lastname: Vellozzi
authors.forename: K
authors.initials: K
authors.lastname: Buchacz
authors.forename: R
authors.initials: R
authors.lastname: Baker
authors.forename: P R
authors.initials: PR
authors.lastname: Spradling
authors.forename: J
authors.initials: J
authors.lastname: Richardson
authors.forename: A
authors.initials: A
authors.lastname: Moorman
authors.forename: E
authors.initials: E
authors.lastname: Tedaldi
authors.forename: M
authors.initials: M
authors.lastname: Durham
authors.forename: J
authors.initials: J
authors.lastname: Ward
authors.forename: J T
authors.initials: JT
authors.lastname: Brooks
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000378:metabolism; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000472:pathogenicity*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006679:HIV Seropositivity; D016174:Hepacivirus / Q000472:pathogenicity*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D014481:United States
chemical_list: D000410:Alanine Transaminase